Developing smarter assessment solutions
Addressing Important Health Issues
Quadrant Biosciences is an epigenetic diagnostics company with an initial focus on the early detection of autism spectrum disorder, Parkinson’s Disease, concussion injuries, and other large-scale health issues
Autism Spectrum Disorder (ASD) is a medical condition that affects a person’s communication abilities and social skills, and often causes repetitive patterns of behavior and a narrow range of interests. The number of children diagnosed annually with ASD has increased significantly between 2002 and 2014, from one in 150 to one in 59.
Although clinical research has demonstrated that early diagnosis and therapeutic intervention leads to the best long-term prognosis, the average age of diagnosis for ASD in the United States is over 4 years of age. Clarifi was designed to aid in the clinical diagnosis of ASD in children 18 to 83 months of age, expediting access to important intervention services.
Clarifi ASD is an easy to administer, non-invasive, molecular test that accurately identifies children likely to have ASD. This test provides objective support for earlier diagnosis, when treatment is most efficacious. Clarifi is developed in cooperation with SUNY Upstate Medical Center and Penn State College of Medicine. This groundbreaking technology is expected to be commercially available in 2019.
Situation: Concussion Diagnosis
This year in the US alone, 1.6 to 3.8 million athletes will experience a sports-related concussion. Despite increased public awareness, the standard tools used to evaluate and treat a concussion — self-reported symptoms and expert opinion — offer poor reliability and sensitivity. Moreover, identifying a reliable biomarker to objectively diagnose concussion has remained elusive. Until now.
Solution: Epigenetic Saliva Test for Concussion
Research we are conducting in cooperation with Penn State College of Medicine and SUNY Upstate Medical University, may change that. Focusing on epigenetic microRNA in the saliva, we have identified a novel and accurate biomarker for concussion in children. Among the significant findings of this research include:
Saliva is a Rich Source – microRNA’s have been found in relative abundance in the saliva which, when coupled with their unique epigenetic properties, make them attractive biomarker candidates
Accurate Differentiation – Six microRNAs had parallel changes in CSF and saliva and could accurately separate concussion and control cases
Predictive of Symptom Duration – The study also showed compelling data that this biomarker may be a better predictor of symptom (headache, fatigue, difficulty concentrating, etc) duration than current standard concussion assessments.
Results of this research were published in the highly regarded, peer-reviewed journal JAMA Pediatrics in November 2017.
Situation: Brain Health
Just like measuring blood pressure and cholesterol, checking brain health should be a routine part of preventive healthcare. However, until now there hasn’t been an objective, practical way to assess and track cognitive wellness and balance.
Solution: The ClearEdge Brain Health Toolkit
The ClearEdge Brain Health Toolkit provides an objective, practical way to assess and track cognitive efficiency, balance and symptoms. Developed and validated in cooperation with SUNY Upstate Medical University, the ClearEdge Brain Health Toolkit allows clinicians the ability to establish brain health baselines and longitudinally track these three important metrics over time.
Complete - ClearEdge provides clinicians a suite of tests and assessments to establish baselines and track brain health and wellness over time. The toolkit is comprised of separate tests for cognitive efficiency, balance assessment and symptoms tracking.
Objective - Patient test results are quantitatively analyzed relative to prior performance
Clinically reliable - The preliminary test-retest reliability assessment indicates that the system will be appropriate for clinical decision-making
Evolutionary - Academic research is translated to clinical practice
Cost Effective - The system’s low cost of acquisition and short testing interval facilitate time and revenue efficiencies using existing CPT codes
Portable - The entire system fits in a briefcase; ClearEdge testing can occur almost anywhere
Situation: Parkinson’s Disease
Parkinson’s disease is a chronic, degenerative neurological disorder of the central nervous system. It results from the progressive loss of cells in various parts of the brain that produce dopamine, a chemical messenger responsible for transmitting signals that allow for coordinated movement.
Parkinson’s affects one in 100 people over age 60 and more than five million people worldwide. Currently there is no objective test or biomarker for Parkinson’s Disease, and the rate of misdiagnosis can be relatively high, especially when the diagnosis is made by a non-specialist.
Solution: Parkinson’s Diagnostic Aid
In cooperation with SUNY Upstate Medical University, Quadrant Biosciences has developed a non-invasive, saliva biomarker test highly accurate in characterizing Parkinson’s Disease through an evaluation of human and oral microbiome transcripts. Commercial launch of this technology is expected in 2020.